Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) PT at $55.50

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $55.50.

A number of research analysts have weighed in on TVRD shares. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. Wall Street Zen cut shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Finally, BTIG Research reiterated a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a report on Wednesday, April 1st.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of Tvardi Therapeutics in the fourth quarter worth approximately $204,000. Goldman Sachs Group Inc. boosted its holdings in Tvardi Therapeutics by 37.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock valued at $142,000 after acquiring an additional 9,102 shares during the period. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at $92,000. Quadrature Capital Ltd bought a new position in Tvardi Therapeutics in the 4th quarter valued at $90,000. Finally, Headlands Technologies LLC bought a new position in Tvardi Therapeutics in the 2nd quarter valued at $80,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Price Performance

Shares of NASDAQ TVRD opened at $3.01 on Tuesday. Tvardi Therapeutics has a 1-year low of $2.75 and a 1-year high of $43.65. The business’s 50 day moving average is $3.49 and its two-hundred day moving average is $5.35. The stock has a market capitalization of $28.23 million, a P/E ratio of -0.54 and a beta of 0.16.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.23). As a group, equities research analysts anticipate that Tvardi Therapeutics will post -2.01 earnings per share for the current fiscal year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.